7ZA.F ASCELIA PHARMA AB

Healthcare Biotechnology Frankfurt Exchange
0.0390 EUR
Close of Nov 11, 2026
0.0001 0.3725
Market cap
EUR 5.21M
P/E
-
P/B
0.66x
ROE
-63.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 7ZA.F undervalued?

Graham number

The Graham number of ASCELIA PHARMA AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ASCELIA PHARMA AB fundamental analysis

No fundamental analysis for ASCELIA PHARMA AB yet.

ASCELIA PHARMA AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ASCELIA PHARMA AB

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncol…

Full company profile